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in JapanAn incredible impact on lung cancer treatment resulted
from the 2004 discovery of an epidermal growth factor
receptor (EGFR) driver mutation by two groups in Boston
[1,2]. This discovery was like a super nova that suddenly
shone in the universe of lung cancer investigation. Although
in 2002 Japan was the ﬁrst country to approve geﬁtinib, a
quinazoline-based kinase inhibitor of the intracellular kinase
domain of EGFR, why geﬁtinib was super-effective in some
cases but not in others remained an enigma. In addition,
Japanese chest physicians had traumatic experiences with
drug-induced interstitial lung disease, among the worst
adverse events caused by geﬁtinib (or other EGFR-tyrosine
kinase inhibitors [TKIs]), with a 5% incidence and 2% mortal-
ity; this was likely speciﬁc to the Japanese population.
The EGFR driver mutation was discovered via reverse
genetics. First, the sequencing of the EGFR gene in geﬁtinib-
effective patients revealed a group of limited alterations in
the kinase domain: speciﬁcally L858R on exon 21, a 3-base
deletion on exon 19, and other more minor alterations.
Second, an amazing ethnic difference in the incidence of
EGFR driver mutations was revealed. The reported incidence
ranged from 60% to 70% among non-smoking patients with
lung adenocarcinoma in Asian countries, including Japan.
This type of accumulation of a particular mutation was ﬁrst
reported in 2002 for the BRAF gene in patients with mela-
noma. Of course, the Philadelphia chromosome in chronic
myelogenous leukemia is a historical equivalent to the
accumulation of a genomic alteration with a malignant
phenotype. Third, geﬁtinib exhibited a 10-fold higher afﬁnity
for EGFR with a mutated kinase, indicating that the target of
EGFR-TKI is a mutated EGFR protein and that the drug acts by
shutting down the altered survival signals and inducing
apoptosis in lung adenocarcinoma cells. Several groups
including ours, the North East Japan Study Group (NEJSG),
rushed to evaluate the clinical relevance in the phase II and
III clinical trials.
Apart from the EGFR driver mutation, in 2007 Soda and
Mano's colleagues in Japan searched growth-related genes
and identiﬁed a particular fusion gene, named EML4-ALK, as a
responsible driver gene in lung cancer [3]. The prevalence of
EML4-ALK is 5% in patients with non-small-cell lung cancer
(NSCLC) with particular pathologic characteristics. Because
an anaplastic lymphoma kinase (ALK) inhibitor was under
clinical trial for hematologic malignancies, a clinical trial of-NC-ND license.crizotinib was initiated without time lag for NSCLC patients
harboring the EML4-ALK fusion gene. Crizotinib was approved
in the USA in 2011, representing an amazing short-term
clinical development from mutation discovery to the market.
Several genes with fusion-type rearrangements were
reported at much lower incidence rates. Therefore, as men-
tioned above, the ﬁrst 10 years of the 21st century demon-
strated a historic milestone in lung cancer studies.
In this issue, the featured articles in Respiratory Investiga-
tion begin in the ﬁeld of lung cancer. Dr. Yoichi Nakanishi, an
associate editor of Respiratory Investigation, selected ﬁve
attractive topics related to lung cancer in Japan during these
10–15 years. Sawabata described the Japanese Joint Commit-
tee of Lung Cancer Registry and introduced survival curves
for surgical patients, with an overall 5-year survival rate of
52% in 2004. Suda et al. introduced the current status of
surgical treatment for lung cancer in Japan, including video-
assisted thoracic surgery (VATS), robotic maneuvers, and
sublobar resection. Kawano et al. reviewed for the ﬁrst time
the current status and future perspectives of eight active
cooperative lung cancer study groups in Japan, along with
their landmark investigator-initiated clinical trials. Toyokawa
summarized ALK rearrangement in lung cancer, the study of
which was initialized in Japan. Finally, Takeuchi discussed
clinical the signiﬁcance of EGFR-TKIs while highlighting their
sensitivity and resistance, and focused on the role of the gene
encoding BIM (BCL2L11). The readers will have a comprehen-
sive overview of the directions taken by Japanese doctors
working on lung cancer treatments.
Ten years after the super-nova-like discovery of the EGFR
driver mutation, the 2014 American Society of Clinical Oncol-
ogy (ASCO) meeting in Chicago likely opened new pages for
these exciting developments in lung cancer treatment. The
directions include novel combinations of EGFR-TKIs and
several antibodies or cytotoxic agents in patients harboring
EGFR driver mutations. An initial trial of these new directions
was reported at ASCO2011: a phase I feasibility study of
irreversible EGFR-TKI (afatinib) and anti-EGFR antibody for
patients with EGFR mutations who were resistant after ﬁrst-
line treatment. The ﬁnal result was recently published with a
promising waterfall response [4]. Three unique results from
Japanese clinical trials were presented at ASCO2014. These
involved regimens of geﬁtinib plus bevacizumab, erlotinib
plus bevacizumab, and geﬁtinib plus concurrent pemetrexed
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amazing combination effects on progression-free survival
were observed at approximately 18 months. Of course, we
do not know the biological backgrounds of these combinator-
ial regimens. One suggestive paper was published by Akbay
and Koyama, who showed that in a mouse model, EGFR
driver-positive tumors provided a cancer environment
with PD-1-positive immune-barriers and high levels of the
pro-cancerous cytokines interleukin 6, transforming growth
factor beta, vascular endothelial growth factor, and proe-
pithelin in the mouse lung bronchoalveolar lavage ﬂuid [5].
In the very near future, breaking of the immune-privileged
environment by using antibodies against adhesive molecules
to control regulatory T cells will be introduced into NSCLC
therapy. Also, next generation EGFR-TKIs that act against the
resistant T790M mutation will be examined in phase III
clinical trials. Altogether, although these agents are limited
to patients with EGFR driver mutations, doctors will be able to
use multiple treatment modalities to ﬁght lung cancer. Of
course, these new developments will beneﬁt patient care,
particularly a large number of patients of Asian ethnicity who
harbor EGFR driver mutations.http://dx.doi.org/10.1016/j.resinv.2014.10.001
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